Page last updated: 2024-12-05

streptogramin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Streptogramin B: A specific streptogramin group B antibiotic produced by Streptomyces graminofaciens and other bacteria. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pristinamycin IA : A cyclodepsipeptide that is (together with pristinamycin IIA) a component of pristinamycin, an oral streptogramin antibiotic produced by Streptomyces pristinaespiralis. Pristinamycin exhibits bactericidal activity against Gram positive organisms including methicillin-resistant Staphylococcus aureus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11136668
CHEMBL ID1256399
CHEBI ID8417
SCHEMBL ID13176900
MeSH IDM0374395

Synonyms (37)

Synonym
ostreogrycin b
4-[4-(dimethylamino)-n-methyl-l-phenylalanine]virginiamycin s1
pristinamycin ia
streptogramin b
antibiotic 899
vernamycin balpha; virginiamycin s1, 4-(4-(dimethylamino)-n-methyl-l-phenylalanine)-
antibiotic pa 114 b1
brn 0078387
antibiotic pa 114b
mikamycin ia
virginiamycin s1, 4-(4(dimethylamino)-n-methyl-l-phenylalanine)-
nsc 92554
pa 114b
antibiotic pa 114b1
chebi:8417 ,
CHEMBL1256399
4-(4-(dimethylamino)-n-methyl-l-phenylalanine)virginiamycin s1
4-27-00-09718 (beilstein handbook reference)
unii-v50xj0nc3i
v50xj0nc3i ,
pristinamycin p 1
pa-114b
n-((3-hydroxy-2-pyridinyl)carbonyl)-l-threonyl-(2r)-2-aminobutanoyl-l-prolyl-4-(dimethylamino)-n-methyl-l-phenylalanyl-(2s)-4-oxo-2-piperidinecarbonyl-(2s)-2-phenylglycine (6->13)-lactone
pristinamycin ia [mi]
vernamycin b, .alpha.
vernamycin b.alpha. [mi]
mikamycin b [mi]
streptogramin b [mi]
HY-A0279A
CS-5850
n-[(6r,9s,10r,13s,15as,22s,24as)-22-{[4-(dimethylamino)phenyl]methyl}-6-ethyl-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyldocosahydro-12h-pyrido[2,1-f]pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacyclononadecin-9-yl]-3-hydroxypyridine-2-carboxamide
SCHEMBL13176900
J-018376
n-((6r,9s,10r,13s,15as,22s,24as)-22-(4-(dimethylamino)benzyl)-6-ethyl-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyldocosahydro-12h-pyrido[2,1-f]pyrrolo[2,1-l][1]oxa[4,7,10,13,16]pentaazacyclononadecin-9-yl)-3-hydroxypicolinamide
Q14035740
F85430
DTXSID701028335

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"5 to 640 mg/kg/day of XRP 2868 fractionated for 3-, 6-, 12-, and 24-h dosing regimens."( Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.
Andes, D; Craig, WA, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cyclodepsipeptideA depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID679903TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) (Vinblastine: 0.05 uM, Pristinamycin IA: 100 uM) in Caco-2 cells1995European journal of pharmacology, Jan-16, Volume: 288, Issue:2
Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID520088Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID520087Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AheABC efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID71054Compound was tested for photoinhibition of Escherichia coli (CIP 548T); Resistant1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Nitroglycosylated meso-arylporphyrins as photoinhibitors of gram positive bacteria.
AID520084Antimicrobial activity against Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID520085Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID520083Antimicrobial activity against aheB-deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID520086Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AcrAB efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID520082Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID679250TP_TRANSPORTER: transepithelial transport (basal to apical) in Caco-2 cells1995European journal of pharmacology, Jan-16, Volume: 288, Issue:2
Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID206391Compound was tested for photoinhibition of Staphylococcus aureus(CIP 53156); No data1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Nitroglycosylated meso-arylporphyrins as photoinhibitors of gram positive bacteria.
AID519833Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID520081Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID519834Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (132)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (2.27)18.7374
1990's2 (1.52)18.2507
2000's52 (39.39)29.6817
2010's64 (48.48)24.3611
2020's11 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other132 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]